SURAKSHA Suraksha Diagnostic Q3 FY26 results (Oct–Dec 2025) and concall
Management summary
- Suraksha Diagnostic Limited reported robust Q3 FY26 results with total income growing 30.3% YoY to INR 783.09 million.
- Strong volume growth and strategic expansion into genomics..
- While EBITDA margins compressed temporarily to 30.6% due to new center ramp-up costs, management is focused on achieving scale and expects margin improvement from Q3 FY27.
- The company is aggressively expanding its network and strengthening its genomics vertical, maintaining a healthy net cash position.
Source: Inve concall analysis and management guidance record.
Highlights
-
Total income for Q3 FY26 grew by a solid 30.3% year-on-year to INR 783.09 million, driven by volume expansion and product mix.
-
Tests performed in Q3 FY26 increased by 30.7% year-over-year to 2.06 million, indicating strong operational growth.
-
The company successfully commissioned 12 new centers in nine months, with an additional 6 facilities in the execution phase.
-
The genomics and molecular vertical, 'Suraksha Sutra,' has shown positive clinical adoption, with a current run rate of INR 2.1-2.2 million per month and a target of INR 4+ crores for FY27.
What they filed
Q3 FY26: revenue up 28.8%, net profit up 33.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 59 | 64 | 70 | 76 | 76 +29% |
| EBITDA | 18 | 20 | 24 | 24 | 23 +28% |
| Net profit | 6 | 8 | 10 | 9 | 8 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
FY26 Revenue Growth Revenue · FY26 · High confidence better than 15%
Previously 15% → better than 15%
Margin
FY26 EBITDA Margin Margin · FY26 · High confidence around 32%
Previously 33-34% → around 32%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Q3 EBITDA Margins and Seasonality Direct
The Q3 margins are always the quarter three is the weakest quarter in healthcare. That is almost a given for... it's a seasonal thing basically and that's almost a given for any kind of healthcare anywhere.
Clarifies that the lower Q3 EBITDA margins are a seasonal effect common in the healthcare industry, not a company-specific issue.
Asked by Dhruv Maheshwari
Current Run Rate for Genomics Business Direct
So currently what we are running at is around INR2.1, INR2.2 million a month we are running. So last quarter Q3 we kind of reached at around INR53 lakhs.
Provides specific, current financial performance data for the high-growth genomics segment, which is a key strategic focus.
Asked by Dhruv Maheshwari
Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 6 risks, concerns & management red flags
- 5 watchlist triggers for Q4 FY26
- +6 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





